Amgen

SEP 9, 2026 · PHASE 1 TRIAL

Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity

ClinicalTrials.gov

This is a Phase 1 safety and tolerability study with no results posted; the registry record describes planned enrollment and endpoints only, without outcome data.

SEP 8, 2026 · PHASE 3 TRIAL

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

ClinicalTrials.gov

This is a Phase 3 clinical trial registry record with no reported results; the study is active but not recruiting, and efficacy outcomes have not yet been posted.

AUG 20, 2026 · INTERVENTIONAL STUDY

Expanded Access of Sotorasib

ClinicalTrials.gov

This is a clinical trial registry record describing an expanded access programme with no results reported; it documents a planned intervention in a defined population but carries no efficacy or safety outcome data.

AUG 14, 2026 · PHASE 3 TRIAL

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

ClinicalTrials.gov

This is a registered but actively recruiting Phase 3 trial with no reported results; the registry record describes planned design and endpoints only, not outcomes.

AUG 7, 2026 · PHASE 1 TRIAL

A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous Presentations

ClinicalTrials.gov

Phase 1 pharmacokinetic study of a new drug formulation in a completed trial; results not yet reported in this registry record.

AUG 4, 2026 · PHASE 3 TRIAL

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

ClinicalTrials.gov

This is a registered Phase 3 trial with no results posted; efficacy and safety remain unknown pending trial completion and analysis.

JUL 16, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Neupogen (Labeling)

U.S. Food and Drug Administration

FDA supplemental approval for labeling changes to an established drug; does not report clinical trial data or efficacy evidence.

JUL 15, 2026 · REGULATORY LABEL UPDATE

FDA supplemental approval: Repatha (Labeling)

U.S. Food and Drug Administration

FDA supplemental approval for labeling change to evolocumab; does not contain clinical trial data and conveys only that regulatory authorization was granted.